| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | KRP; AAT7; MLCK; MLCK1; MMIHS; MYLK1; smMLCK; MLCK108; MLCK210; MSTP083 |
| Entrez GeneID | 4638 |
| clone | 7F2B11 |
| WB Predicted band size | 210kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human MYLK (AA:1375-1524) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与MYLK抗体相关的研究文献概览(经综合整理，非真实文献，仅供参考格式)：
1. **"MYLK-mediated cytoskeletal remodeling in cancer metastasis"**
- **作者**: Smith A, et al. (2018)
- **摘要**: 研究通过MYLK特异性抗体(Western blot/免疫荧光)证实，MYLK在乳腺癌细胞中过表达，并通过激活肌球蛋白轻链磷酸化促进细胞迁移和侵袭，提示其在转移中的关键作用。
2. **"Endothelial barrier dysfunction regulated by MYLK isoforms"**
- **作者**: Chen L, et al. (2020)
- **摘要**: 利用针对不同MYLK异构体(如长链/短链)的特异性抗体，发现短链MYLK在炎症因子刺激下加剧血管内皮通透性，为肺水肿治疗提供新靶点。
3. **"A novel MYLK antibody validates genetic variants in aortic dissection"**
- **作者**: Wang X, et al. (2021)
- **摘要**: 开发高亲和力MYLK单克隆抗体，用于检测主动脉瘤患者组织样本中MYLK蛋白表达缺失，揭示其与MYLK基因突变的临床相关性。
如需真实文献，建议通过PubMed或Google Scholar检索关键词“MYLK antibody”、“myosin light chain kinase antibody”筛选实验类论文。
**Background of MYLK Antibodies**
MYLK (myosin light-chain kinase) is a calcium/calmodulin-dependent enzyme that phosphorylates the regulatory light chain of myosin, triggering smooth muscle contraction and modulating cytoskeletal reorganization in non-muscle cells. The MYLK gene encodes multiple isoforms, including the long (MYLK1) and short (MYLK2) forms, which exhibit tissue-specific expression. MYLK1 is predominantly expressed in smooth muscle and endothelial cells, playing a critical role in vascular tone regulation, while MYLK2 is associated with cardiac and skeletal muscle function.
MYLK dysregulation has been implicated in cardiovascular diseases (e.g., hypertension, aortic aneurysm), inflammatory conditions, and cancer metastasis. Antibodies targeting MYLK are essential tools for studying its expression, localization, and activity in these contexts. They enable detection of MYLK isoforms via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific antibodies may distinguish phosphorylated (active) or total MYLK, aiding in research on signaling pathways involving Rho-associated kinase (ROCK) or calcium-dependent contraction mechanisms.
Recent studies also explore MYLK's role in endothelial barrier dysfunction and tumor cell migration, highlighting its potential as a therapeutic target. Commercial MYLK antibodies are typically validated in human, mouse, or rat models, with applications spanning basic research and clinical diagnostics. However, isoform specificity and cross-reactivity remain key considerations during experimental design.
×
